{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T18:51:42Z","timestamp":1793559102257,"version":"4.5.0"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s12325-021-01766-y","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T10:04:25Z","timestamp":1622801065000},"page":"3589-3621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-5873","authenticated-orcid":false,"given":"Roberto","family":"De Giorgio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furio Massimino","family":"Zucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Chiarioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Mercadante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Stefano","family":"Corazziari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Caraceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Odetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Marinangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"1766_CR1","unstructured":"Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. U.S. opioid dispensing rate maps. https:\/\/www.cdc.gov\/drugoverdose\/maps\/rxrate-maps.html. Accessed 30 Dec 2020."},{"key":"1766_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ajgsup.2014.7","volume":"2","author":"S Dorn","year":"2014","unstructured":"Dorn S, Lembo A, Cremonini F. Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. Am J Gastroenterol. 2014;2:31\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1766_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","volume":"10","author":"H Breivik","year":"2006","unstructured":"Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287\u2013333.","journal-title":"Eur J Pain"},{"key":"1766_CR4","unstructured":"Legge 15 marzo 2010, n. 38. Disposizioni per garantire l\u2019accesso alle cure palliative e alla terapia del dolore. (10G0056) (GU Serie Generale n. 65 del 19-03-2010). https:\/\/www.gazzettaufficiale.it\/gunewsletter\/dettaglio.jsp?service=1&datagu=2010-03-19&task=dettaglio&numgu=65&redaz=010G0056&tmstp=1269600292070. Accessed 1 Apr 2020."},{"issue":"4","key":"1766_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ejp.1337","volume":"23","author":"C Bosetti","year":"2019","unstructured":"Bosetti C, Santucci C, Radrezza S, et al. Trends in the consumption of opioids for the treatment of severe pain in Europe, 1990\u20132016. Eur J Pain. 2019;23(4):697\u2013707.","journal-title":"Eur J Pain"},{"issue":"3","key":"1766_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrgastro.2017.141","volume":"15","author":"E Szigethy","year":"2018","unstructured":"Szigethy E, Knisely M, Drossman D. Opioid misuse in gastroenterology and non-opioid management of abdominal pain. Rev Nat Rev Gastroenterol Hepatol. 2018;15(3):168\u201380.","journal-title":"Rev Nat Rev Gastroenterol Hepatol"},{"key":"1766_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/1756283X15578608","volume":"8","author":"AD Nelson","year":"2015","unstructured":"Nelson AD, Camilleri M. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. Therap Adv Gastroenterol. 2015;8:206\u201320.","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"1766_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1378\/chest.09-1543","volume":"137","author":"DA Mahler","year":"2010","unstructured":"Mahler DA, Selecky PA, Harrod CG, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010;137(3):674\u201391.","journal-title":"Chest"},{"issue":"4","key":"1766_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/1074248418757009","volume":"23","author":"H Rawal","year":"2018","unstructured":"Rawal H, Patel BM. Opioids in cardiovascular disease: therapeutic options. J Cardiovasc Pharmacol Ther. 2018;23(4):279\u201391.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"1766_CR10","first-page":"25","volume":"2","author":"Gruppo Italiano per la Costipazione indotta da Oppioidi","year":"2009","unstructured":"Gruppo Italiano per la Costipazione indotta da Oppioidi. Raccomandazioni per la gestione della costipazione indotta da oppioidi. Riv Soc Itali Med Gen. 2009;2:25\u201332.","journal-title":"Riv Soc Ital Med Gen"},{"issue":"1","key":"1766_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2050640618818305","volume":"7","author":"AD Farmer","year":"2019","unstructured":"Farmer AD, Drewes AM, Chiarioni G, et al. Pathophysiology and management of opioid-induced constipation: European Expert Consensus Statement. United Eur Gastroenterol J. 2019;7(1):7\u201320.","journal-title":"United Eur Gastroenterol J"},{"key":"1766_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/ajgsup.2014.4","volume":"2","author":"P Holzer","year":"2014","unstructured":"Holzer P. Pharmacology of opioids and their effects on gastrointestinal function. Am J Gastroenterol Suppl. 2014;2:9\u201316.","journal-title":"Am J Gastroenterol Suppl"},{"issue":"Suppl 2","key":"1766_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1743-3150.2004.00553.x","volume":"16","author":"C Sternini","year":"2004","unstructured":"Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004;16(Suppl 2):3\u201316.","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"1766_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0306-4522(97)00227-3","volume":"81","author":"D Bagnol","year":"1997","unstructured":"Bagnol D, Mansour A, Akil H, Watson SJ. Cellular localisation and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience. 1997;81(2):579\u201391.","journal-title":"Neuroscience"},{"issue":"1\u20132","key":"1766_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0169-328X(96)00266-5","volume":"46","author":"J Fickel","year":"1997","unstructured":"Fickel J, Bagnol D, Watson SJ, Akil H. Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Brain Res Mol Brain Res. 1997;46(1\u20132):1\u20138.","journal-title":"Brain Res Mol Brain Res"},{"issue":"2","key":"1766_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1517\/13543784.16.2.181","volume":"16","author":"P Holzer","year":"2007","unstructured":"Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs. 2007;16(2):181\u201394.","journal-title":"Expert Opin Investig Drugs"},{"key":"1766_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/164_2016_116","volume":"239","author":"JJ Galligan","year":"2017","unstructured":"Galligan JJ, Sternini C. Insights into the role of opioid receptors in the GI tract: experimental evidence and therapeutic relevance. Handb Exp Pharmacol. 2017;239:363\u201378.","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"1766_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1124\/jpet.111.186320","volume":"340","author":"M Kang","year":"2012","unstructured":"Kang M, Maguma HT, Smith TH, et al. The role of \u03b2-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract. J Pharmacol Exp Ther. 2012;340(3):567\u201376.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1766_CR19","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/nmo.12443","volume":"26","author":"HI Akbarali","year":"2014","unstructured":"Akbarali HI, Inkisar A, Dewey WL. Site and mechanism of morphine tolerance in the gastrointestinal tract. Neurogastroenterol Motil. 2014;26(10):1361\u20137.","journal-title":"Neurogastroenterol Motil"},{"issue":"1","key":"1766_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ajgsup.2014.5","volume":"2","author":"JJ Galligan","year":"2014","unstructured":"Galligan JJ, Akbarali HI. Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl. 2014;2(1):17\u201321.","journal-title":"Am J Gastroenterol Suppl"},{"issue":"Suppl 2","key":"1766_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1743-3150.2004.00554.x","volume":"16","author":"JD Wood","year":"2004","unstructured":"Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16(Suppl 2):17\u201328.","journal-title":"Neurogastroenterol Motil"},{"issue":"14","key":"1766_CR22","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.2165\/11634970-000000000-00000","volume":"72","author":"C Brock","year":"2012","unstructured":"Brock C, Olesen SS, Olesen AE, et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72(14):1847\u201365.","journal-title":"Drugs"},{"key":"1766_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.sjpain.2015.12.005","volume":"11","author":"AM Drewes","year":"2016","unstructured":"Drewes AM, Munkholm P, Simr\u00e9n M, et al. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction\u2014recommendations of the Nordic Working Group. Scand J Pain. 2016;11:111\u201322.","journal-title":"Scand J Pain"},{"issue":"1\u20132","key":"1766_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0169-328X(98)00051-5","volume":"56","author":"S Roy","year":"1998","unstructured":"Roy S, Liu HC, Loh HH. mu-Opioid receptor-knockout mice: the role of mu-opioid receptor in gastrointestinal transit. Brain Res Mol Brain Res. 1998;56(1\u20132):281\u20133.","journal-title":"Brain Res Mol Brain Res"},{"issue":"8","key":"1766_CR25","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S1542-3565(05)00434-9","volume":"3","author":"J Gonenne","year":"2005","unstructured":"Gonenne J, Camilleri M, Ferber I, et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol. 2005;3(8):784\u201391.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"1766_CR26","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/gut.2003.035246","volume":"53","author":"R Penagini","year":"2004","unstructured":"Penagini R, Allocca M, Cant\u00f9 P, et al. Relationship between motor function of the proximal stomach and transient lower oesophageal sphincter relaxation after morphine. Gut. 2004;53(9):1227\u201331.","journal-title":"Gut"},{"issue":"1","key":"1766_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/00365529709025060","volume":"32","author":"WM Sun","year":"1997","unstructured":"Sun WM, Read NW, Verlinden M. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol. 1997;32(1):34\u20138.","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"1766_CR28","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1046\/j.1365-2036.2002.01320.x","volume":"16","author":"ND Hawkes","year":"2002","unstructured":"Hawkes ND, Rhodes J, Evans BK, et al. Naloxone treatment for irritable bowel syndrome\u2014a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther. 2002;16(9):1649\u201354.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1766_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1517\/13543784.2011.563236","volume":"20","author":"K Smith","year":"2011","unstructured":"Smith K, Hopp M, Mundin G, et al. Naloxone as part of a prolonged release oxycodone\/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs. 2011;20(4):427\u201339.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"1766_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.5056\/jnm15175","volume":"22","author":"JL Poulsen","year":"2016","unstructured":"Poulsen JL, Nilsson M, Brock C, et al. The impact of opioid treatment on regional gastrointestinal transit. J Neurogastroenterol Motil. 2016;22(2):282\u201391.","journal-title":"J Neurogastroenterol Motil"},{"issue":"5","key":"1766_CR31","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/MEG.0000000000000574","volume":"28","author":"M Nilsson","year":"2016","unstructured":"Nilsson M, Poulsen JL, Brock C, et al. Opioid-induced bowel dysfunction in healthy volunteers assessed with questionnaires and MRI. Eur J Gastroenterol Hepatol. 2016;28(5):514\u201324.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"1766_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11894-013-0363-z","volume":"16","author":"JD Huizinga","year":"2014","unstructured":"Huizinga JD, Chen J-H. Interstitial cells of Cajal: update on basic and clinical science. Curr Gastroenterol Rep. 2014;16(1):363.","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"1766_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.5056\/jnm17058","volume":"24","author":"JL Poulsen","year":"2018","unstructured":"Poulsen JL, Mark EB, Brock C, et al. Colorectal transit and volume during treatment with prolonged-release oxycodone\/naloxone versus oxycodone plus macrogol 3350. J Neurogastroenterol Motil. 2018;24(1):119\u201327.","journal-title":"J Neurogastroenterol Motil"},{"issue":"4","key":"1766_CR34","doi-asserted-by":"publisher","first-page":"602","DOI":"10.5056\/jnm18079","volume":"25","author":"AE Olesen","year":"2019","unstructured":"Olesen AE, Gr\u00f8nlund D, Mark EB, et al. Effects of naloxegol on gastrointestinal transit and colonic fecal volume in healthy participants receiving oxycodone. J Neurogastroenterol Motil. 2019;25(4):602\u201310.","journal-title":"J Neurogastroenterol Motil"},{"key":"1766_CR35","doi-asserted-by":"crossref","unstructured":"Thiagarajah JR, Verkman AS. Water transport in the gastrointestinal tract. In: Johnson LR, Barrett KE, editors. Physiology of the gastrointestinal tract. 4th ed. Burlington: Elsevier; 2006.","DOI":"10.1016\/B978-012088394-3\/50075-1"},{"issue":"1","key":"1766_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jpainsymman.2007.01.017","volume":"35","author":"J Thomas","year":"2008","unstructured":"Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manag. 2008;35(1):103\u201313.","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"1766_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0163-7258(95)02053-5","volume":"69","author":"A De Luca","year":"1996","unstructured":"De Luca A, Coupar IM. Insight into opioid action in the intestinal tract. Pharmacol Ther. 1996;69(2):103\u201315.","journal-title":"Pharmacol Ther"},{"issue":"2 Pt 1","key":"1766_CR38","first-page":"G259","volume":"270","author":"LL Clarke","year":"1996","unstructured":"Clarke LL, Harline MC. CFTR is required for cAMP inhibition of intestinal Na+ absorption in a cystic fibrosis mouse model. Am J Physiol. 1996;270(2 Pt 1):G259\u201367.","journal-title":"Am J Physiol"},{"key":"1766_CR39","first-page":"1","volume":"137","author":"K Kunzelmann","year":"1999","unstructured":"Kunzelmann K. The cystic fibrosis transmembrane conductance regulator and its function in epithelial transport. Rev Physiol Biochem Pharmacol. 1999;137:1\u201370.","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"1766_CR40","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1146\/annurev.physiol.62.1.535","volume":"62","author":"KE Barrett","year":"2000","unstructured":"Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol. 2000;62:535\u201372.","journal-title":"Annu Rev Physiol"},{"issue":"10","key":"1766_CR41","first-page":"1837","volume":"18","author":"S M\u00fcller-Lissner","year":"2017","unstructured":"M\u00fcller-Lissner S, Bassotti G, Coffin B, et al. Opioid-induced constipation and bowel dysfunction: a clinical guideline. Pain Med. 2017;18(10):1837\u201363.","journal-title":"Pain Med"},{"issue":"7","key":"1766_CR42","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003495-200363070-00003","volume":"63","author":"A Kurz","year":"2003","unstructured":"Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63(7):649\u201371.","journal-title":"Drugs"},{"issue":"1\u20132","key":"1766_CR43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000069707","volume":"67","author":"H Glad","year":"2003","unstructured":"Glad H, Ainsworth MA, Svendsen P, et al. Effect of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on pancreatic, hepatic and duodenal mucosal bicarbonate secretion in the pig. Digestion. 2003;67(1\u20132):56\u201366.","journal-title":"Digestion"},{"issue":"5A Suppl","key":"1766_CR44","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.1016\/S0002-9610(01)00782-6","volume":"182","author":"M Pappagallo","year":"2001","unstructured":"Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A Suppl):11S-18S.","journal-title":"Am J Surg"},{"issue":"3","key":"1766_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S2468-1253(18)30008-6","volume":"3","author":"AD Farmer","year":"2018","unstructured":"Farmer AD, Holt CB, Downes TJ, et al. Pathophysiology, diagnosis, and management of opioid-induced constipation. Lancet Gastroenterol Hepatol. 2018;3(3):203\u201312.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1766_CR46","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/j.1742-1241.2007.01415.x","volume":"61","author":"SJ Panchal","year":"2007","unstructured":"Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181\u20137.","journal-title":"Int J Clin Pract"},{"issue":"12","key":"1766_CR47","first-page":"1045","volume":"14","author":"G Rosti","year":"2010","unstructured":"Rosti G, Gatti A, Costantini A, et al. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci. 2010;14(12):1045\u201350.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"11","key":"1766_CR48","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1007\/s00520-019-04688-2","volume":"27","author":"M Rossi","year":"2019","unstructured":"Rossi M, Casale G, Badiali D, et al. Opioid-induced bowel dysfunction: suggestions from a multidisciplinary expert board. Support Care Cancer. 2019;27(11):4083\u201390.","journal-title":"Support Care Cancer"},{"issue":"Suppl 1","key":"1766_CR49","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1111\/pme.12911","volume":"16","author":"LR Webster","year":"2015","unstructured":"Webster LR. Opioid-induced constipation. Pain Med. 2015;16(Suppl 1):S16\u201321.","journal-title":"Pain Med"},{"issue":"3","key":"1766_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11894-017-0560-2","volume":"19","author":"DM Brenner","year":"2017","unstructured":"Brenner DM, Stern E, Cash BD. Opioid-related constipation in patients with non-cancer pain syndromes: a review of evidence-based therapies and justification for a change in nomenclature. Curr Gastroenterol Rep. 2017;19(3):12.","journal-title":"Curr Gastroenterol Rep"},{"issue":"2","key":"1766_CR51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3344\/kjp.2019.32.2.69","volume":"32","author":"K Lang-Illievich","year":"2019","unstructured":"Lang-Illievich K, Bornemann-Cimenti H. Opioid-induced constipation: a narrative review of therapeutic options in clinical management. Korean J Pain. 2019;32(2):69\u201378.","journal-title":"Korean J Pain"},{"issue":"1","key":"1766_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/MCG.0000000000000246","volume":"49","author":"J Gaertner","year":"2015","unstructured":"Gaertner J, Siemens W, Camilleri M, et al. Definitions and outcome measures of clinical trials regarding opioid induced constipation: a systematic review. J Clin Gastroenterol. 2015;49(1):9\u201316.","journal-title":"J Clin Gastroenterol"},{"key":"1766_CR53","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/gut.33.6.818","volume":"33","author":"KW Heaton","year":"1992","unstructured":"Heaton KW, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut. 1992;33:818\u201324.","journal-title":"Gut"},{"issue":"6","key":"1766_CR54","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","volume":"150","author":"DA Drossman","year":"2016","unstructured":"Drossman DA, Hasler WL. Rome IV\u2014functional GI disorders: disorders of gut\u2013brain interaction. Gastroenterology. 2016;150(6):1257\u201361.","journal-title":"Gastroenterology"},{"key":"1766_CR55","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","volume":"150","author":"BE Lacy","year":"2016","unstructured":"Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393\u2013407.","journal-title":"Gastroenterology"},{"issue":"8","key":"1766_CR56","doi-asserted-by":"publisher","first-page":"e72608","DOI":"10.1371\/journal.pone.0072608","volume":"8","author":"P Iovino","year":"2013","unstructured":"Iovino P, Chiarioni G, Bilancio G, et al. New onset of constipation during long-term physical inactivity: a proof-of-concept study on the immobility-induced bowel changes. PLoS ONE. 2013;8(8):e72608.","journal-title":"PLoS ONE"},{"issue":"9","key":"1766_CR57","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11894-013-0344-2","volume":"15","author":"GA Ketwaroo","year":"2013","unstructured":"Ketwaroo GA, Cheng V, Lembo A. Opioid-induced bowel dysfunction. Curr Gastroenterol Rep. 2013;15(9):344.","journal-title":"Curr Gastroenterol Rep"},{"issue":"5","key":"1766_CR58","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/14656566.2018.1561863","volume":"20","author":"W Leppert","year":"2019","unstructured":"Leppert W, Zajaczkowska R, Wordliczek J. The role of oxycodone\/naloxone in the management of patients with pain and opioid-induced constipation. Expert Opin Pharmacother. 2019;20(5):511\u201322.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1766_CR59","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1053\/j.gastro.2018.08.018","volume":"156","author":"B Hanson","year":"2019","unstructured":"Hanson B, Siddique SM, Scarlett Y, Sultan S, American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute technical review on the medical management of opioid-induced constipation. Gastroenterology. 2019;156(1):229\u201353.","journal-title":"Gastroenterology"},{"issue":"Suppl 4","key":"1766_CR60","doi-asserted-by":"publisher","first-page":"iv111","DOI":"10.1093\/annonc\/mdy148","volume":"29","author":"PJ Larkin","year":"2018","unstructured":"Larkin PJ, Cherny NI, La Carpia D, et al. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv111\u201325.","journal-title":"Ann Oncol"},{"key":"1766_CR61","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.2147\/DDDT.S32684","volume":"9","author":"W Leppert","year":"2015","unstructured":"Leppert W. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Des Dev Ther. 2015;9:2215\u201331.","journal-title":"Drug Des Dev Ther"},{"issue":"5","key":"1766_CR62","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4140\/TCP.n.2017.285","volume":"32","author":"C Allen","year":"2017","unstructured":"Allen C, Zarowitz BJ, O\u2019Shea T, et al. Clinical and functional characteristics of nursing facility residents with opioid-induced constipation. Consult Pharm. 2017;32(5):285\u201398.","journal-title":"Consult Pharm"},{"issue":"1","key":"1766_CR63","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","volume":"10","author":"TJ Bell","year":"2009","unstructured":"Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10(1):35\u201342.","journal-title":"Pain Med"},{"issue":"7295","key":"1766_CR64","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/bmj.322.7295.1154","volume":"322","author":"L Allan","year":"2001","unstructured":"Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ. 2001;322(7295):1154\u20138.","journal-title":"BMJ"},{"issue":"3","key":"1766_CR65","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.pain.2004.09.019","volume":"112","author":"E Kalso","year":"2004","unstructured":"Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372\u201380.","journal-title":"Pain"},{"issue":"5","key":"1766_CR66","doi-asserted-by":"publisher","first-page":"R1046","DOI":"10.1186\/ar1782","volume":"7","author":"RA Moore","year":"2005","unstructured":"Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7(5):R1046\u201351.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1766_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5055\/jom.2006.0023","volume":"2","author":"RT Brown","year":"2006","unstructured":"Brown RT, Zuelsdorff M, Fleming M. Adverse effects and cognitive function among primary care patients taking opioids for chronic nonmalignant pain. J Opioid Manag. 2006;2(3):137\u201346.","journal-title":"J Opioid Manag"},{"issue":"5","key":"1766_CR68","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.clinthera.2007.05.016","volume":"29","author":"M Hale","year":"2007","unstructured":"Hale M, Tudor IC, Khanna S, Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther. 2007;29(5):874\u201388.","journal-title":"Clin Ther"},{"issue":"12","key":"1766_CR69","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/j.1365-2036.2008.03689.x","volume":"27","author":"SF Cook","year":"2008","unstructured":"Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27(12):1224\u201332.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1766_CR70","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.clinthera.2013.03.002","volume":"35","author":"P Richards","year":"2013","unstructured":"Richards P, Gimbel JS, Minkowitz HS, et al. Comparison of the efficacy and safety of dual-opioid treatment with morphine plus oxycodone versus oxycodone\/acetaminophen for moderate to severe acute pain after total knee arthroplasty. Clin Ther. 2013;35(4):498\u2013511.","journal-title":"Clin Ther"},{"issue":"8","key":"1766_CR71","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40266-016-0381-2","volume":"33","author":"S Chokhavatia","year":"2016","unstructured":"Chokhavatia S, John ES, Bridgeman MB, Dixit D. Constipation in elderly patients with noncancer pain: focus on opioid-induced constipation. Drugs Aging. 2016;33(8):557\u201374.","journal-title":"Drugs Aging"},{"issue":"4","key":"1766_CR72","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/2050640616659967","volume":"5","author":"P Ducrott\u00e9","year":"2017","unstructured":"Ducrott\u00e9 P, Milce J, Soufflet C, Fabry C. Prevalence and clinical features of opioid-induced constipation in the general population: a French study of 15,000 individuals. United Eur Gastroenterol J. 2017;5(4):588\u2013600.","journal-title":"United Eur Gastroenterol J"},{"issue":"12","key":"1766_CR73","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/pm\/pny002","volume":"19","author":"A Gupta","year":"2018","unstructured":"Gupta A, Coyne KS, Datto C, Venuti C. The burden of opioid-induced constipation in younger patients with chronic noncancer pain. Pain Med. 2018;19(12):2459\u201368.","journal-title":"Pain Med"},{"key":"1766_CR74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12325-012-0074-0","volume":"30","author":"A Gatti","year":"2013","unstructured":"Gatti A, Casali M, Lazzari M, et al. Prolonged-release oxycodone\/naloxone in nonmalignant pain: single-center study in patients with constipation. Adv Ther. 2013;30:41\u201359.","journal-title":"Adv Ther"},{"issue":"3 Suppl","key":"1766_CR75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/10732748040110S302","volume":"11","author":"SC McMillan","year":"2004","unstructured":"McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control. 2004;11(3 Suppl):3\u20139.","journal-title":"Cancer Control"},{"issue":"6","key":"1766_CR76","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/annonc\/mdw097","volume":"27","author":"O Corli","year":"2016","unstructured":"Corli O, Floriani I, Roberto A, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV \u2018real life\u2019 trial on the variability of response to opioids. Ann Oncol. 2016;27(6):1107\u201315.","journal-title":"Ann Oncol"},{"issue":"5","key":"1766_CR77","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.jpainsymman.2019.02.009","volume":"57","author":"O Corli","year":"2019","unstructured":"Corli O, Santucci C, Corsi N, et al. The burden of opioid adverse events and the influence on cancer patients\u2019 symptomatology. J Pain Symptom Manag. 2019;57(5):899-908.e6.","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"1766_CR78","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jpainsymman.2016.05.030","volume":"52","author":"E Zecca","year":"2016","unstructured":"Zecca E, Brunelli C, Bracchi P, et al. Comparison of the tolerability profile of controlled-release oral morphine and oxycodone for cancer pain treatment: an open-label randomized controlled trial. J Pain Symptom Manag. 2016;52(6):783-94.e6.","journal-title":"J Pain Symptom Manag"},{"issue":"3","key":"1766_CR79","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/0304-3959(95)00180-8","volume":"64","author":"B Donner","year":"1996","unstructured":"Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64(3):527\u201334.","journal-title":"Pain"},{"key":"1766_CR80","first-page":"175","volume-title":"Principles and practice of palliative care and supportive oncology","author":"S Mercadante","year":"2013","unstructured":"Mercadante S. Diarrhea, malabsorption, constipation. In: Berger AM, Shuster JL, Von Roenn JH, editors. Principles and practice of palliative care and supportive oncology. 4th ed. Lippincott: Philadelphia; 2013. p. 175\u201392.","edition":"4"},{"key":"1766_CR81","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/gutjnl-2018-316001","volume":"68","author":"P Luthra","year":"2019","unstructured":"Luthra P, Burr NE, Brenner DM, Ford AC. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. Gut. 2019;68:34\u201344.","journal-title":"Gut"},{"issue":"1","key":"1766_CR82","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/0269216311418869","volume":"26","author":"SH Ahmedzai","year":"2012","unstructured":"Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone\/naloxone prolonged-release tablets in patients with moderate\/severe, chronic cancer pain. Palliat Med. 2012;26(1):50\u201360.","journal-title":"Palliat Med"},{"issue":"9","key":"1766_CR83","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00520-011-1205-x","volume":"19","author":"S Mercadante","year":"2011","unstructured":"Mercadante S, Ferrera P, Adile C. High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer. 2011;19(9):1471\u20132.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1766_CR84","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1517\/13543784.2013.752460","volume":"22","author":"S Mercadante","year":"2013","unstructured":"Mercadante S, Giarratano A. Combined oral prolonged-release oxycodone and naloxone in chronic pain management. Expert Opin Investig Drugs. 2013;22(1):161\u20136.","journal-title":"Expert Opin Investig Drugs"},{"key":"1766_CR85","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2147\/CIA.S105821","volume":"11","author":"M Lazzari","year":"2016","unstructured":"Lazzari M, Marcassa C, Natoli S, et al. Switching to low-dose oral prolonged-release oxycodone\/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation. Clin Interv Aging. 2016;11:641\u20139.","journal-title":"Clin Interv Aging"},{"issue":"7","key":"1766_CR86","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/03007995.2017.1358702","volume":"34","author":"S Mercadante","year":"2018","unstructured":"Mercadante S, Masedu F, Maltoni M, et al. The prevalence of constipation at admission and after 1 week of palliative care: a multicenter study. Curr Med Res Opin. 2018;34(7):1187\u201392.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"1766_CR87","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1191\/026921698674125048","volume":"12","author":"NP Sykes","year":"1998","unstructured":"Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med. 1998;12(5):375\u201382.","journal-title":"Palliat Med"},{"issue":"1","key":"1766_CR88","doi-asserted-by":"publisher","first-page":"33","DOI":"10.23736\/S0375-9393.16.11099-5","volume":"83","author":"L Miceli","year":"2017","unstructured":"Miceli L, Bednarova R, Di Cesare M, et al. Outpatient therapeutic chronic opioid consumption in Italy: a one-year survey. Minerva Anestesiol. 2017;83(1):33\u201340.","journal-title":"Minerva Anestesiol"},{"issue":"2","key":"1766_CR89","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.4081\/or.2014.5309","volume":"6","author":"G Fanelli","year":"2014","unstructured":"Fanelli G, Cherubino P, Compagnone C. Opioid use for chronic pain management in Italy: results from the Orthopedic Instant Pain Survey Project. Orthop Rev (Pavia). 2014;6(2):5309.","journal-title":"Orthop Rev (Pavia)"},{"issue":"8","key":"1766_CR90","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1177\/2050640618786145","volume":"6","author":"V Andresen","year":"2018","unstructured":"Andresen V, Banerji V, Hall G, et al. The patient burden of opioid-induced constipation: new insights from a large, multinational survey in five European countries. United Eur Gastroenterol J. 2018;6(8):1254\u201366.","journal-title":"United Eur Gastroenterol J"},{"key":"1766_CR91","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12876-015-0366-3","volume":"15","author":"R De Giorgio","year":"2015","unstructured":"De Giorgio R, Ruggeri E, Stanghellini V, et al. Chronic constipation in the elderly: a primer for the gastroenterologist. BMC Gastroenterol. 2015;15:130.","journal-title":"BMC Gastroenterol"},{"key":"1766_CR92","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.sjpain.2017.01.006","volume":"15","author":"J S\u00f8ndergaard","year":"2017","unstructured":"S\u00f8ndergaard J, Christensen HN, Ibsen R, et al. Healthcare resource use and costs of opioid-induced constipation among non-cancer and cancer patients on opioid therapy: a nationwide register-based cohort study in Denmark. Scand J Pain. 2017;15:83\u201390.","journal-title":"Scand J Pain"},{"key":"1766_CR93","doi-asserted-by":"crossref","unstructured":"Veiga DR, Mendon\u00e7a L, Sampaio R, et al. Incidence and health related quality of life of opioid-induced constipation in chronic noncancer pain patients: a prospective multicentre cohort study. Pain Res Treat. 2018;2018:5704627.","DOI":"10.1155\/2018\/5704627"},{"issue":"6","key":"1766_CR94","first-page":"CD006332","volume":"6","author":"B Candy","year":"2018","unstructured":"Candy B, Jones L, Vickerstaff V, et al. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. Cochrane Database Syst Rev. 2018;6(6):CD006332.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1766_CR95","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/mpo.10254","volume":"40","author":"H Flogeg\u00e5rd","year":"2003","unstructured":"Flogeg\u00e5rd H, Ljungman G. Characteristics and adequacy of intravenous morphine infusions in children in a paediatric oncology setting. Med Pediatr Oncol. 2003;40(4):233\u20138.","journal-title":"Med Pediatr Oncol"},{"issue":"7","key":"1766_CR96","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1089\/jpm.2014.0364","volume":"18","author":"JE Flerlage","year":"2015","unstructured":"Flerlage JE, Baker JN. Methylnaltrexone for opioid-induced constipation in children and adolescents and young adults with progressive incurable cancer at the end of life. J Palliat Med. 2015;18(7):631\u20133.","journal-title":"J Palliat Med"},{"issue":"5","key":"1766_CR97","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jpainsymman.2010.02.019","volume":"40","author":"F Hjalte","year":"2010","unstructured":"Hjalte F, Berggren AC, Bergendahl H, Hjortsberg C. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manag. 2010;40(5):696\u2013703.","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"1766_CR98","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12876-019-1097-7","volume":"19","author":"MS Keller","year":"2019","unstructured":"Keller MS, Jusufagic A, Spiegel BMR. Patient and provider differences in the treatment of opioid-induced constipation: a qualitative study. BMC Gastroenterol. 2019;19(1):182.","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"1766_CR99","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/0269216312450358","volume":"27","author":"L Dhingra","year":"2013","unstructured":"Dhingra L, Shuk E, Grossman B, et al. A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med. 2013;27(5):447\u201356.","journal-title":"Palliat Med"},{"issue":"3","key":"1766_CR100","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s12325-017-0480-4","volume":"34","author":"RS Epstein","year":"2017","unstructured":"Epstein RS, Teagarden JR, Cimen A, et al. When people with opioid-induced constipation speak: a patient survey. Adv Ther. 2017;34(3):725\u201331.","journal-title":"Adv Ther"},{"issue":"3","key":"1766_CR101","first-page":"236","volume":"22","author":"RJ LoCasale","year":"2016","unstructured":"LoCasale RJ, Datto C, Wilson H, et al. The burden of opioid-induced constipation: discordance between patient and health care provider reports. J Manag Care Spec Pharm. 2016;22(3):236\u201345.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"1766_CR102","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/papr.12445","volume":"17","author":"RL Rauck","year":"2017","unstructured":"Rauck RL, Hong K-SJ, North J. Opioid-induced constipation survey in patients with chronic noncancer pain. Pain Pract. 2017;17(3):329\u201335.","journal-title":"Pain Pract"},{"issue":"7","key":"1766_CR103","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3109\/00365521.2015.1007079","volume":"50","author":"P Patel","year":"2015","unstructured":"Patel P, Bercik P, Morgan DG, et al. Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol. 2015;50(7):816\u201323.","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"1766_CR104","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3109\/00365521.2012.758767","volume":"48","author":"L Shim","year":"2013","unstructured":"Shim L, Talley NJ, Boyce P, et al. Stool characteristics and colonic transit in irritable bowel syndrome: evaluation at two time points. Scand J Gastroenterol. 2013;48(3):295\u2013301.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"1766_CR105","doi-asserted-by":"publisher","first-page":"561","DOI":"10.5056\/jnm17022","volume":"23","author":"V Jaruvongvanich","year":"2017","unstructured":"Jaruvongvanich V, Patcharatrakul T, Gonlachanvit S. Prediction of delayed colonic transit using Bristol stool form and stool frequency in Eastern constipated patients: a difference from the West. J Neurogastroenterol Motil. 2017;23(4):561\u20138.","journal-title":"J Neurogastroenterol Motil"},{"key":"1766_CR106","unstructured":"International Longevity Centre (ILC) UK. The burden of constipation in our ageing population: working towards better solutions. London: ILC-UK; 2013."},{"issue":"3","key":"1766_CR107","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jpainsymman.2004.06.013","volume":"29","author":"M Goodman","year":"2005","unstructured":"Goodman M, Low J, Wilkinson S. Constipation management in palliative care: a survey of practices in the United Kingdom. J Pain Symptom Manag. 2005;29(3):238\u201344.","journal-title":"J Pain Symptom Manag"},{"key":"1766_CR108","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijscr.2017.11.060","volume":"42","author":"R Poitras","year":"2018","unstructured":"Poitras R, Warrena D, Oyogoa S. Opioid drugs and stercoral perforation of the colon: case report and review of literature. Int J Surg Case Rep. 2018;42:94\u20137.","journal-title":"Int J Surg Case Rep"},{"issue":"4","key":"1766_CR109","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/2050640616663439","volume":"5","author":"K Krogh","year":"2017","unstructured":"Krogh K, Chiarioni G, Whitehead W. Management of chronic constipation in adults. United Eur Gastroenterol J. 2017;5(4):465\u201372.","journal-title":"United Eur Gastroenterol J"},{"issue":"10","key":"1766_CR110","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cgh.2007.06.013","volume":"5","author":"DMS Grunkemeier","year":"2007","unstructured":"Grunkemeier DMS, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol. 2007;5(10):1126\u201339.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"1766_CR111","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2468-1253(16)30217-5","volume":"2","author":"AD Farmer","year":"2017","unstructured":"Farmer AD, Gallagher J, Bruckner-Holt C, Aziz Q. Narcotic bowel syndrome. Lancet Gastroenterol Hepatol. 2017;2(5):361\u20138.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1766_CR112","doi-asserted-by":"publisher","first-page":"164","DOI":"10.7326\/L19-0798","volume":"173","author":"E Loomis","year":"2020","unstructured":"Loomis E, Bajwa J, Kaizuka S. Buprenorphine-naloxone as a novel treatment of narcotic bowel syndrome: a case report. Ann Intern Med. 2020;173(2):164\u20136.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1766_CR113","first-page":"153","volume":"21","author":"TP Black","year":"2012","unstructured":"Black TP, Manolakis CS, Di Palma JA. \u201cRed flag\u201d evaluation yield in irritable bowel syndrome. J Gastrointestin Liver Dis. 2012;21(2):153\u20136.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"3","key":"1766_CR114","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/03007995.2016.1273204","volume":"33","author":"M Due\u00f1as","year":"2017","unstructured":"Due\u00f1as M, Mendon\u00e7a L, Sampaio R, et al. Reliability and validity of the Bowel Function Index for evaluating opioid-induced constipation: translation, cultural adaptation and validation of the Portuguese version (BFI-P). Curr Med Res Opin. 2017;33(3):563\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1766_CR115","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/ajg.2010.431","volume":"106","author":"M Camilleri","year":"2011","unstructured":"Camilleri M, Rothman M, Ho KF, Etropolski M. Validation of a bowel function diary for assessing opioid-induced constipation. Am J Gastroenterol. 2011;106(3):497\u2013506.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1766_CR116","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40271-014-0087-7","volume":"8","author":"KS Coyne","year":"2015","unstructured":"Coyne KS, Currie BM, Holmes WC, Crawley JA. Assessment of a stool symptom screener and understanding the opioid-induced constipation symptom experience. Patient. 2015;8(4):317\u201327.","journal-title":"Patient"},{"issue":"1","key":"1766_CR117","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/147323001103900106","volume":"39","author":"MA Ueberall","year":"2011","unstructured":"Ueberall MA, M\u00fcller-Lissner S, Buschmann-Kramm C, Bosse B. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res. 2011;39(1):41\u201350.","journal-title":"J Int Med Res"},{"issue":"4","key":"1766_CR118","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3111\/13696990903430481","volume":"12","author":"AM Rentz","year":"2009","unstructured":"Rentz AM, Yu R, M\u00fcller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12(4):371\u201383.","journal-title":"J Med Econ"},{"issue":"3","key":"1766_CR119","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1185\/03007995.2012.657301","volume":"28","author":"P Ducrott\u00e9","year":"2012","unstructured":"Ducrott\u00e9 P, Causse C. The Bowel Function Index: a new validated scale for assessing opioid-induced constipation. Curr Med Res Opin. 2012;28(3):457\u201366.","journal-title":"Curr Med Res Opin"},{"key":"1766_CR120","unstructured":"Sizar O, Gupta M. Opioid induced constipation. Treasure Island: StatPearls; 2020."},{"issue":"7","key":"1766_CR121","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1177\/0269216308096908","volume":"22","author":"PJ Larkin","year":"2008","unstructured":"Larkin PJ, Sykes NP, Centeno C, et al. The management of constipation in palliative care: clinical practice recommendations. Palliat Med. 2008;22(7):796\u2013807.","journal-title":"Palliat Med"},{"issue":"1","key":"1766_CR122","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1053\/j.gastro.2018.07.016","volume":"156","author":"SD Crockett","year":"2019","unstructured":"Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the medical management of opioid-induced constipation. Gastroenterology. 2019;156(1):218\u201326.","journal-title":"Gastroenterology"},{"issue":"12","key":"1766_CR123","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11864-019-0686-6","volume":"20","author":"R Mes\u00eda","year":"2019","unstructured":"Mes\u00eda R, Virizuela Echaburu JA, G\u00f3mez J, et al. Opioid-induced constipation in oncological patients: new strategies of management. Curr Treat Opt Oncol. 2019;20(12):91.","journal-title":"Curr Treat Opt Oncol"},{"issue":"1","key":"1766_CR124","first-page":"95","volume":"92","author":"WA Voderholzer","year":"1997","unstructured":"Voderholzer WA, Schatke W, M\u00fchldorfer BE, et al. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol. 1997;92(1):95\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"1766_CR125","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2982.2007.00974.x","volume":"19","author":"JY Chang","year":"2007","unstructured":"Chang JY, Locke GR, Schleck CD, et al. Risk factors for chronic constipation and a possible role of analgesics. Neurogastroenterol Motil. 2007;19(11):905\u201311.","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"1766_CR126","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1742-1241.1995.tb09896.x","volume":"49","author":"RH Jones","year":"1995","unstructured":"Jones RH, Tait CL. Gastrointestinal side-effects of NSAIDs in the community. Br J Clin Pract. 1995;49(2):67\u201370.","journal-title":"Br J Clin Pract"},{"issue":"6","key":"1766_CR127","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2165\/00003495-199957060-00003","volume":"57","author":"PN Maton","year":"1999","unstructured":"Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999;57(6):855\u201370.","journal-title":"Drugs"},{"issue":"9","key":"1766_CR128","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.disamonth.2011.05.006","volume":"57","author":"P Deepak","year":"2011","unstructured":"Deepak P, Ehrenpreis ED. Constipation. Dis Mon. 2011;57(9):511\u20137.","journal-title":"Dis Mon"},{"key":"1766_CR129","doi-asserted-by":"crossref","unstructured":"Bartz S. Constipation and fecal incontinence. In: Ham R, Sloane P, Bernard M, editors. Primary care geriatrics: a case-based approach. 5th ed. Philadelphia: Mosby\/Elsevier; 2006.","DOI":"10.1016\/B978-032303930-7.50031-6"},{"issue":"2","key":"1766_CR130","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","volume":"13","author":"A Caraceni","year":"2012","unstructured":"Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58-68.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1766_CR131","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1007\/BF02087913","volume":"41","author":"E Corazziari","year":"1996","unstructured":"Corazziari E, Badiali D, Habib FI, et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci. 1996;41(8):1636\u201342.","journal-title":"Dig Dis Sci"},{"issue":"8","key":"1766_CR132","first-page":"960","volume":"15","author":"R De Giorgio","year":"2011","unstructured":"De Giorgio R, Cestari R, Corinaldesi R, et al. Use of macrogol 4000 in chronic constipation. Rev Eur Rev Med Pharmacol Sci. 2011;15(8):960\u20136.","journal-title":"Rev Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"1766_CR133","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1053\/j.gastro.2017.01.027","volume":"152","author":"JS Fordtran","year":"2017","unstructured":"Fordtran JS, Hofmann AF. Seventy years of polyethylene glycols in gastroenterology: the journey of PEG 4000 and 3350 from nonabsorbable marker to colonoscopy preparation to osmotic laxative. Gastroenterology. 2017;152(4):675\u201380.","journal-title":"Gastroenterology"},{"issue":"10","key":"1766_CR134","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/j.1552-4604.1997.tb04264.x","volume":"37","author":"MD Freedman","year":"1997","unstructured":"Freedman MD, Schwartz HJ, Roby R, Fleisher S. Tolerance and efficacy of polyethylene glycol 3350\/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. J Clin Pharmacol. 1997;37(10):904\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1766_CR135","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/gut.2010.227132","volume":"60","author":"AC Ford","year":"2011","unstructured":"Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011;60(2):209\u201318.","journal-title":"Gut"},{"issue":"4","key":"1766_CR136","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/gut.46.4.522","volume":"46","author":"E Corazziari","year":"2000","unstructured":"Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut. 2000;46(4):522\u20136.","journal-title":"Gut"},{"issue":"8","key":"1766_CR137","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/pme.12724","volume":"16","author":"KS Coyne","year":"2015","unstructured":"Coyne KS, Margolis MK, Yeomans K, et al. Opioid-induced constipation among patients with chronic noncancer pain in the United States, Canada, Germany, and the United Kingdom: laxative use, response, and symptom burden over time. Pain Med. 2015;16(8):1551\u201365.","journal-title":"Pain Med"},{"key":"1766_CR138","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2147\/DDDT.S221278","volume":"14","author":"JV Pergolizzi","year":"2020","unstructured":"Pergolizzi JV, Christo PJ, LeQuang JA, Magnusson P. The use of peripheral \u03bc-opioid receptor antagonists (PAMORA) in the management of opioid-induced constipation: an update on their efficacy and safety. Drug Des Dev Ther. 2020;14:1009\u201325.","journal-title":"Drug Des Dev Ther"},{"key":"1766_CR139","volume-title":"Stipsi e occlusione intestinale maligna nel paziente oncologico: valutazione dei sintomi, cause, diagnosi e trattamento","author":"R Giusti","year":"2017","unstructured":"Giusti R, Lucchesi M, Ripamonti CI. Stipsi e occlusione intestinale maligna nel paziente oncologico: valutazione dei sintomi, cause, diagnosi e trattamento. Milan: Springer Healthcare Italia; 2017."},{"issue":"22","key":"1766_CR140","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1056\/NEJMoa0707377","volume":"358","author":"J Thomas","year":"2008","unstructured":"Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332\u20134.","journal-title":"N Engl J Med"},{"issue":"1","key":"1766_CR141","first-page":"39","volume":"7","author":"N Slatkin","year":"2009","unstructured":"Slatkin N, Thomas J, Lipman GA, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39\u201346.","journal-title":"J Support Oncol"},{"issue":"7","key":"1766_CR142","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1089\/jpm.2014.0362","volume":"18","author":"J Bull","year":"2015","unstructured":"Bull J, Wellman CV, Israel RJ, et al. Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. J Palliat Med. 2015;18(7):593\u2013600.","journal-title":"J Palliat Med"},{"issue":"2","key":"1766_CR143","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2217\/pmt-2019-0045","volume":"10","author":"BH Chamberlain","year":"2020","unstructured":"Chamberlain BH, Rhiner M, Slatkin NE, et al. Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer. Pain Manag. 2020;10(2):73\u201384.","journal-title":"Pain Manag"},{"issue":"1","key":"1766_CR144","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jval.2010.11.003","volume":"14","author":"SS Iyer","year":"2011","unstructured":"Iyer SS, Randazzo BP, Tzanis EL, et al. Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value Health. 2011;14(1):177\u201383.","journal-title":"Value Health"},{"issue":"5","key":"1766_CR145","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jpain.2010.11.008","volume":"12","author":"E Michna","year":"2011","unstructured":"Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12(5):554\u201362.","journal-title":"J Pain"},{"issue":"2","key":"1766_CR146","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jhm.943","volume":"7","author":"L Anissian","year":"2012","unstructured":"Anissian L, Schwartz HW, Vincent K, et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med. 2012;7(2):67\u201372.","journal-title":"J Hosp Med"},{"issue":"6","key":"1766_CR147","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/papr.12535","volume":"17","author":"R Rauck","year":"2017","unstructured":"Rauck R, Slatkin NE, Stambler N, et al. Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Pract. 2017;17(6):820\u20138.","journal-title":"Pain Pract"},{"issue":"3","key":"1766_CR148","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/00325481.2016.1149017","volume":"128","author":"N Mehta","year":"2016","unstructured":"Mehta N, O\u2019Connell K, Giambrone GP, et al. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review. Postgrad Med. 2016;128(3):282\u20139.","journal-title":"Postgrad Med"},{"key":"1766_CR149","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2147\/TCRM.S80749","volume":"12","author":"W Siemens","year":"2016","unstructured":"Siemens W, Becker G. Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes. Ther Clin Risk Manag. 2016;12:401\u201312.","journal-title":"Ther Clin Risk Manag"},{"key":"1766_CR150","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4137\/CMO.S4867","volume":"5","author":"S Bader","year":"2011","unstructured":"Bader S, Jaroslawski K, Blum HE, Becker G. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insights Oncol. 2011;5:201\u201311.","journal-title":"Clin Med Insights Oncol"},{"key":"1766_CR151","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2147\/PPA.S99412","volume":"11","author":"SC Yoon","year":"2017","unstructured":"Yoon SC, Bruner HC. Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem. Patient Prefer Adherence. 2017;11:1265\u201371.","journal-title":"Patient Prefer Adherence"},{"issue":"25","key":"1766_CR152","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1310246","volume":"370","author":"WD Chey","year":"2014","unstructured":"Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387\u201396.","journal-title":"N Engl J Med"},{"issue":"7","key":"1766_CR153","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/apt.12899","volume":"40","author":"L Webster","year":"2014","unstructured":"Webster L, Chey WD, Tack J, et al. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014;40(7):771\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1766_CR154","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/bmjspcare-2020-002249","volume":"11","author":"MC Dols","year":"2021","unstructured":"Dols MC, Zambrano CB, Guti\u00e9rrez LC, et al. Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis. BMJ Support Palliat Care. 2021;11(1):25\u201331.","journal-title":"BMJ Support Palliat Care"},{"issue":"8","key":"1766_CR155","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S2468-1253(17)30105-X","volume":"2","author":"M Hale","year":"2017","unstructured":"Hale M, Wild J, Reddy J, et al. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol. 2017;2(8):555\u201364.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"1766_CR156","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/j.pain.0000000000001174","volume":"159","author":"LR Webster","year":"2018","unstructured":"Webster LR, Nalamachu S, Morlion B, et al. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study. Pain. 2018;159(5):987\u201394.","journal-title":"Pain"},{"issue":"34","key":"1766_CR157","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","volume":"35","author":"N Katakami","year":"2017","unstructured":"Katakami N, Harada T, Murata T, et al. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017;35(34):3859\u201366.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1766_CR158","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1124\/jpet.119.264515","volume":"373","author":"T Kanemasa","year":"2020","unstructured":"Kanemasa T, Koike K, Takase K, et al. Pharmacological profile of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist: comparison with naloxone and naloxegol. J Pharmacol Exp Ther. 2020;373(3):438\u201344.","journal-title":"J Pharmacol Exp Ther"},{"key":"1766_CR159","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1007\/s10620-010-1229-y","volume":"55","author":"CEJ Sloots","year":"2010","unstructured":"Sloots CEJ, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55:2912\u201321.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"1766_CR160","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1097\/j.pain.0000000000001754","volume":"161","author":"DM Brenner","year":"2020","unstructured":"Brenner DM, Argoff CE, Fox SM, et al. Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study. Pain. 2020;161(5):1027\u201336.","journal-title":"Pain"},{"key":"1766_CR161","doi-asserted-by":"crossref","unstructured":"Prichard D, Norton C, Bharucha AE. Management of opioid-induced constipation. Br J Nurs. 2016;25(10):S4\u2013S5, S8\u2013S11.","DOI":"10.12968\/bjon.2016.25.10.S4"},{"issue":"12","key":"1766_CR162","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1111\/pme.12937","volume":"16","author":"CE Argoff","year":"2015","unstructured":"Argoff CE, Brennan MJ, Camilleri M, et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015;16(12):2324\u201337.","journal-title":"Pain Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01766-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01766-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01766-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T14:14:04Z","timestamp":1699107244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01766-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":162,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1766"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01766-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"assertion":[{"value":"24 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version was revised due to update in funding note.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}